-

bluebird bio Announces September Investor Events

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will participate in fireside chats at the following upcoming investor conferences:

  • Morgan Stanley 21st Annual Global Healthcare Conference, Monday, September 11, at 12:15 p.m. ET at the Sheraton, New York, NY
  • Baird 2023 Global Healthcare Conference, Tuesday, September 12, at 2:00 p.m. ET at the Intercontinental New York Barclay, New York, NY

To access the live webcast of bluebird bio’s fireside chats, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the events.

About bluebird bio, Inc.

bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.

With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.

For more information, visit bluebirdbio.com or follow us on social media at @bluebirdbio, LinkedIn, Instagram and YouTube.

bluebird bio is a trademark of bluebird bio, Inc.

Contacts

Investors:
Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com

Media:
Jess Rowlands, 857-299-6103
jess.rowlands@bluebirdbio.com

Industry:

bluebird bio, Inc.

NASDAQ:BLUE
Release Versions
English

Contacts

Investors:
Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com

Media:
Jess Rowlands, 857-299-6103
jess.rowlands@bluebirdbio.com

More News From bluebird bio, Inc.

Genetix Participates in the American Society of Hematology’s (ASH) Exclusive Press Program & Shares Recent Patient Experience Data from U.S. Commercial Gene Therapy Implementation

SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc. today announced their participation in the American Society of Hematology’s (ASH) exclusive press program ahead of the 67th ASH annual meeting in Orlando, Florida (December 6-9, 2025). Genetix’s abstract Accelerating access to gene therapy: Lessons from commercial implementation in sickle cell disease and transfusion-dependent thalassemia was selected by the ASH Program Committee as one of the meeting’s most impactful datasets sub...

Genetix Biotherapeutics to Present Recent Patient Experience Data from U.S. Commercial Gene Therapy Implementation at the 67th American Society of Hematology (ASH) Annual Meeting

SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc. today announced that an analysis of recent patient experience data from the commercial implementation of LYFGENIA™ and ZYNTEGLO™ in the U.S. has been selected for oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida (December 6-9, 2025). “We are pleased to share this analysis for the first time at ASH, which demonstrates the rising acceptance and administration of our one-time gene...

bluebird bio Rebrands as Genetix Biotherapeutics, Returning to Its Foundational Roots

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. today announced it has rebranded as Genetix Biotherapeutics Inc., returning to its foundational roots. Genetix, now strengthened both financially and operationally, is significantly better positioned to harness its decades of scientific innovation and extensive clinical data from hundreds of treated patients to more effectively deliver life-changing genetic therapies. The recently appointed Genetix management team, led by CEO David Meek, is...
Back to Newsroom